Immunohistochemical studies of fascin, MMP-9 overexpression, and proliferating index as prognostic factors in cases of a colon adenocarcinoma

Journal of the Korean Society of Coloproctology

Volumn 25, Issue 6, 2009, Pages 393-400

  Kim, Beom Gyu ^a   Ha, Kyung Won ^a   Park, Jun Suk ^a   Yoo, Jae Hyung ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

Colon adenocarcinoma; Fascin; MMP 9; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE ALPHA (ATP HYDROLYSING); FASCIN; GELATINASE B; UNCLASSIFIED DRUG;

AGED; AGING; ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; COLON; COLON ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RATING SCALE; TISSUE SECTION;

EID: 77953437056     PISSN: 20937822     EISSN: 20937830     Source Type: Journal    
DOI: 10.3393/jksc.2009.25.6.393     Document Type: Article

References (25)

1. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71: 1368-83.
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
3. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
4. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression Signatare of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004; 64:8585-94.
5. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins, and their roles in cell structure and function. Bioassays 2002;24:350-61.
6. Yamashiro-Matsumura S, Matsumura F. Intracellular localization of the 55-kD actin-bundling protein in cultured cells: spatial relationships with actin, alpha-actinin, tropomyosin, and fimbrin. J Cell Biol 1986; 103: 631-40.
7. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003;162:69-80.
8. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chippa A, Valerio M, et al. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 2007;96:1118-26.
9. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl 1:S42-51.
10. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002;86:1876-83.
11. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2O02;8O: 105-10.
12. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005;337:355-62.
13. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
14. Staley BE, Samowitz WS, Bronstein IB, Holden JA. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol 1999;12:356-61.
15. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. Colon and rectum. In: American Joint Comittee on Cancer, editor. AJCC Cancer Staging Manual. 6th ed. New York: Springer-verlag; 2002. p.113-9.
16. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclopoxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002;94:1023-31.
17. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104:54-9.
18. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left sided colon cancers? Annals Surg Oncol 2008;15:2388-94.
19. Adams JC. Roles of fascin in cell adhesion and motility. Xurr Opin Cell Biol 2004;16:590-6.
20. Tilney LG, Connelly PS, Vranich KA, Shaw MK, Guild GM. Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each-link contribute? J Cell Biol 1998;143:121-33.
21. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer an immunohistochemical study of colorectal adenomas and adenocarcinomas. Br J Cancer 2006;6:241-51.
22. Guzinska-Ustymowicz K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenorype of colorectal cancer (CRC). Anticancer Res 2006;26:1589-94.
23. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim BIophys Acta 2004;1705:69-89.
24. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke SA, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154-60.
25. Depowski PL, Rosenthal SI, Brein TP, Stylos S, Johnson RL, Ross JS. Topoisomerase II-alpha expression in breast cancer correlation with outcome variables. Mod Pathol 2000;13:542-7.